CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of non-small cell lung cancer.
  
  LEARNING OBJECTIVES

  • Convey the clinical relevance of a positive ALK testing result to appropriate patients with non-small cell lung cancer (NSCLC), and establish a clinical algorithm to most effectively identify patients harboring these abnormalities.
  • Recall available Phase III data documenting the efficacy of various ALK inhibitors as first-line therapy, and select an optimal treatment approach for newly diagnosed ALK-positive metastatic NSCLC.
  • Evaluate the efficacy and safety of approved ALK inhibitors in patients who have progressed on front-line ALK inhibitor therapy, and counsel patients regarding personalized therapeutic recommendations.
  • Develop an optimal approach to the management of ALK-positive NSCLC with CNS metastases, considering the implications of symptomatology, number of lesions and other factors.
  • Implement a plan of care to recognize and manage the side effects and toxicities associated with approved ALK-directed therapies to support quality of life and continuation of treatment.
  • Understand the biologic rationale for the design of current clinical trials evaluating novel therapeutic approaches for ALK-positive NSCLC, and refer appropriate patients for ongoing research studies.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  D Ross Camidge, MD, PhD
  Professor of Medicine/Oncology
  Joyce Zeff Chair in Lung Cancer Research
  University of Colorado, Anschutz Medical Campus
  Denver, Colorado
  
  Advisory Committee: Apollomics Inc, AstraZeneca Pharmaceuticals LP, Elevation Oncology, Kestrel Therapeutics, Nuvalent; Consulting Agreements: AbbVie Inc, Amgen Inc, AnHeart Therapeutics, Blueprint Medicines, EMD Serono Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc, Medtronic Inc, Mersana Therapeutics Inc, Mirati Therapeutics Inc, OnKure Therapeutics, Ribon Therapeutics, Roche Laboratories Inc, Sanofi, Seagen Inc, Takeda Pharmaceuticals USA Inc, Turning Point Therapeutics Inc; Data and Safety Monitoring Board/Committee: BeiGene Ltd, Biothera Pharmaceuticals Inc, Helsinn Healthcare SA, Hengrui Therapeutics Inc, Lilly; ILD Adjudication Committee: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Mersana Therapeutics Inc; Nonrelevant Financial Relationship: Kestrel Therapeutics (Stock), Puma Biotechnology Inc (NCCN grant review).
  
  Justin F Gainor, MD
  Director, Center for Thoracic Cancers at Massachusetts General Hospital
  Director of Targeted Immunotherapy in the Henri and Belinda Termeer Center for Targeted Therapies
  Associate Professor of Medicine, Harvard Medical School
  Massachusetts General Hospital
  Boston, Massachusetts
  
  Consulting Agreements: Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Gilead Sciences Inc, Helsinn Healthcare SA, Incyte Corporation, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Oncorus, Pfizer Inc, Regeneron Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Contracted Research: Adaptimmune, ALX Oncology, Array BioPharma Inc, a subsidiary of Pfizer Inc, Blueprint Medicines, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Jounce Therapeutics, Merck, Moderna, Novartis, Scholar Rock, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company; Employment (Immediate Family Member): Ironwood Pharmaceuticals.
  
  Professor Ben Solomon, MBBS, PhD
  Medical Oncologist
  Head of Lung Medical Oncology Service
  Peter MacCallum Cancer Centre
  Melbourne, Australia
  
  Advisory Committee: Amgen Inc, AnHeart Therapeutics, Bristol-Myers Squibb Company, D3 Bio, GSK, Janssen Biotech Inc, Lilly, Merck, Novartis, Pfizer Inc, Roche Laboratories Inc, Takeda Pharmaceuticals USA Inc; Contracted Research: Sanofi; Speaker at Education Events: Amgen Inc, Bristol-Myers Squibb Company, Lilly, Merck, Pfizer Inc, Roche Laboratories Inc, Takeda Pharmaceuticals USA Inc.
  
  Professor Solange Peters, MD, PhD
  Head, Medical Oncology
  Chair, Thoracic Malignancies
  Oncology Department
  Lausanne University Hospital (CHUV)
  Lausanne, Switzerland
  
  All Fees to Institution — Advisory Committee and Consulting Agreements: AbbVie Inc, Amgen Inc, Arcus Biosciences, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Biocartis, BioInvent, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Clovis Oncology, Daiichi Sankyo Inc, Debiopharm, F-star Therapeutics, Foundation Medicine, Genentech, a member of the Roche Group, Genzyme Corporation, Gilead Sciences Inc, GSK, Illumina, Incyte Corporation, Ipsen Biopharmaceuticals Inc, IQVIA, iTeos Therapeutics, Janssen Biotech Inc, Lilly, Merck Serono, Merck Sharp & Dohme LLC, Merrimack Pharmaceuticals Inc, Novartis, Novocure Inc, Nykode Therapeutics, Pfizer Inc, PharmaMar, Phosplatin Therapeutics, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Takeda Pharmaceuticals USA Inc; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP, Takeda Pharmaceuticals USA Inc; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Foundation Medicine, Genentech, a member of the Roche Group, GSK, Illumina, Ipsen Biopharmaceuticals Inc, Lilly, Merck Sharp & Dohme LLC, Mirati Therapeutics Inc, Novartis, Pfizer Inc, Sanofi, Takeda Pharmaceuticals USA Inc.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.
  
  This activity is supported by an educational grant from Pfizer Inc.
  
  Release date: March 2023
  Expiration date: March 2024